Quarterly report pursuant to Section 13 or 15(d)

5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2)

v3.8.0.1
5. STOCKHOLDERS' EQUITY (DEFICIT) (Details 2) - USD ($)
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Total stock-based compensation expense $ 514,784 $ 235,877
Research and development    
Total stock-based compensation expense 78,305 52,983
Plasma centers    
Total stock-based compensation expense 7,086 12,751
Selling, general and administrative    
Total stock-based compensation expense 394,858 170,143
Cost of goods sold    
Total stock-based compensation expense $ 34,535 $ 0